- Home
- BMY
as 01-17-2025 4:00pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 115.2B | IPO Year: | N/A |
| Target Price: | $56.29 | AVG Volume (30 days): | 10.8M |
| Analyst Decision: | Hold | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -3.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.35 - $61.08 | Next Earning Date: | 02-06-2025 |
| Revenue: | $47,435,000,000 | Revenue Growth: | 5.56% |
| Revenue Growth (this year): | 7.22% | Revenue Growth (next year): | 0.24% |
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025?
TipRanks
2 days ago
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
Zacks
2 days ago
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
MT Newswires
3 days ago
Update: Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks
The Wall Street Journal
3 days ago
Ozempic Among the Next Drugs Up for Medicare Price Negotiations
Yahoo Finance
3 days ago
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
Zacks
6 days ago
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
MT Newswires
7 days ago
Bristol-Myers Squibb Company Exercises Exclusive License Option for ArsenalBio's AB-4000 Series
Compare BMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.